Harrow Eye Drug Patent Portfolio
Harrow Eye owns 10 orange book drugs protected by 41 US patents with Iheezo having the least patent protection, holding only 1 patent. And Moxeza with maximum patent protection, holding 8 patents. Given below is the list of Harrow Eye's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12059449 | Ophthalmic composition for treatment of dry eye disease | 01 Apr, 2042 | Active |
| US11413323 | Ophthalmic composition for treatment of dry eye disease | 11 Oct, 2039 | Active |
| US11154513 | Semifluorinated compounds | 20 Nov, 2038 | Active |
| US10792271 | Topical formulations of chloroprocaine and methods of using same | 15 Sep, 2038 | Active |
| US10813976 | Ophthalmic compositions comprising ciclosporin | 22 Sep, 2037 | Active |
| US9254286 | Ophthalmic formulations of cetirizine and methods of use | 09 Jan, 2033 | Active |
| US9254286 | Ophthalmic formulations of cetirizine and methods of use | 09 Jul, 2032 | Active |
| US8921337 | Carboxyvinyl polymer-containing nanoparticle suspensions | 31 Mar, 2032 | Active |
| US8614178 | Pharmaceutical composition for treatment of dry eye syndrome | 13 Dec, 2030 | Active |
| US9662398 | Carboxylvinyl polymer-containing nanoparticle suspensions | 01 Dec, 2030 | Active |
| US8829005 | Ophthalmic formulations of cetirizine and methods of use | 15 Sep, 2030 | Active |
| US8829005 | Ophthalmic formulations of cetirizine and methods of use | 15 Mar, 2030 | Active |
| US9750684 | Ophthalmic formulations of cetirizine and methods of use | 15 Mar, 2030 | Active |
| US9993471 | Ophthalmic formulations of cetirizine and methods of use | 15 Mar, 2030 | Active |
| US8128960 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | 17 Dec, 2029 | Active |
| US9132071 | Compositions containing quaternary ammonium compounds | 02 Jun, 2029 | Active |
| US8450311 | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug | 29 May, 2029 | Active |
| US9114168 | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug | 29 May, 2029 | Active |
| US8211880 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | 10 Mar, 2029 | Active |
| US7795316 | Topical ophthalmic compositions containing tobramycin and dexamethasone | 03 Aug, 2028 | Active |
| US8101582 | Topical ophthalmic compositions containing tobramycin and dexamethasone | 19 Dec, 2027 | Active |
| US8450287 | Topical ophthalmic compositions containing tobramycin and dexamethasone | 19 Dec, 2027 | Active |
| US8298568 | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential | 03 Nov, 2027 | Active |
| US7834059 | Topical nepafenac formulations | 31 Jan, 2027 | Active |
| US11612658 | Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same | 27 Jan, 2026 | Active |
| US7973081 | Emulsion compositions containing quaternary ammonium compounds | 27 Jan, 2026 | Active |
| US8524779 | Emulsion compositions containing quaternary ammonium compounds | 27 Jan, 2026 | Active |
| US9220694 | Emulsion compositions containing cetalkonium chloride | 27 Jan, 2026 | Active |
| US9956289 | Emulsion compositions containing quaternary ammonium compounds | 27 Jan, 2026 | Active |
| US8071648 | Topical nepafenac formulations | 02 Dec, 2025 | Active |
| US8324281 | Topical nepafenac formulations | 02 Dec, 2025 | Active |
| US7947295 | Ophthalmic compositions containing a synergistic combination of two polymers | 08 Jun, 2024 | Expired |
| US6716830 | Ophthalmic antibiotic compositions containing moxifloxacin | 29 Mar, 2020 | Expired |
| US7671070 | Method of treating ophthalmic infections with moxifloxacin compositions | 29 Mar, 2020 | Expired |
| US6395294 | Method of visualization of the vitreous during vitrectomy | 13 Jan, 2020 | Expired |
| US6716830 | Ophthalmic antibiotic compositions containing moxifloxacin | 29 Sep, 2019 | Expired |
| US7671070 | Method of treating ophthalmic infections with moxifloxacin compositions | 29 Sep, 2019 | Expired |
| US6403609 | Ophthalmic compositions containing galactomannan polymers and borate | 17 Jul, 2018 | Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives | 04 Sep, 2014 | Expired |
| US5475034 | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | 06 Jun, 2014 | Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives | 04 Mar, 2014 | Expired |
Latest Legal Activities on Harrow Eye's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Harrow Eye.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 09 Jun, 2024 | US8450287 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Jun, 2024 | US9662398 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Apr, 2024 | US8298568 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Apr, 2024 | US10813976 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 Apr, 2024 | US10792271 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 17 Dec, 2023 | US8324281 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 12 Dec, 2023 | US8450287 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 12 Dec, 2023 | US7795316 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 12 Dec, 2023 | US8101582 |
|
Email Notification
Critical
| 12 Dec, 2023 | US8101582 |
|
Email Notification
Critical
| 12 Dec, 2023 | US7795316 |
|
Email Notification
Critical
| 12 Dec, 2023 | US8450287 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 04 Dec, 2023 | US8324281 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 16 Oct, 2023 | US8211880 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 16 Oct, 2023 | US8211880 |
Harrow Eye's Drug Patent Litigations
Harrow Eye's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 12, 2012, against patent number US7671070. The petitioner Apotex Inc., challenged the validity of this patent, with Alcon as the respondent. Click below to track the latest information on how companies are challenging Harrow Eye's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6716830 | October, 2012 |
Terminated-Settled
(15 Nov, 2013)
| Alcon Pharmaceuticals Ltd. | Apotex Inc. |
| US7671070 | October, 2012 |
Terminated-Settled
(15 Nov, 2013)
| Alcon | Apotex Inc. |
Harrow Eye Drug Patents' Oppositions Filed in EPO
Harrow Eye drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 04, 2017, by Reckitt Benckiser (Brands) Limited. This opposition was filed on patent number EP12173896A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP12173896A | Jan, 2017 | Reckitt Benckiser (Brands) Limited | Revoked |
Harrow Eye's Family Patents
Harrow Eye Drug List
Given below is the complete list of Harrow Eye's drugs and the patents protecting them.
1. Iheezo
Iheezo is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10792271 | Topical formulations of chloroprocaine and methods of using same |
15 Sep, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Iheezo's drug page
2. Ilevro
Ilevro is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8921337 | Carboxyvinyl polymer-containing nanoparticle suspensions |
31 Mar, 2032
(7 years from now)
| Active |
| US9662398 | Carboxylvinyl polymer-containing nanoparticle suspensions |
01 Dec, 2030
(5 years from now)
| Active |
| US7947295 | Ophthalmic compositions containing a synergistic combination of two polymers |
08 Jun, 2024
(5 months ago)
| Expired |
| US6403609 | Ophthalmic compositions containing galactomannan polymers and borate |
17 Jul, 2018
(6 years ago)
| Expired |
| US5475034 | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
06 Jun, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ilevro's drug page
3. Moxeza
Moxeza is protected by 8 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8450311 | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
29 May, 2029
(4 years from now)
| Active |
| US9114168 | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
29 May, 2029
(4 years from now)
| Active |
| US6716830
(Pediatric)
| Ophthalmic antibiotic compositions containing moxifloxacin |
29 Mar, 2020
(4 years ago)
| Expired |
| US7671070
(Pediatric)
| Method of treating ophthalmic infections with moxifloxacin compositions |
29 Mar, 2020
(4 years ago)
| Expired |
| US6716830 | Ophthalmic antibiotic compositions containing moxifloxacin |
29 Sep, 2019
(5 years ago)
| Expired |
| US7671070 | Method of treating ophthalmic infections with moxifloxacin compositions |
29 Sep, 2019
(5 years ago)
| Expired |
| US5607942
(Pediatric)
| 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
04 Sep, 2014
(10 years ago)
| Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
04 Mar, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Moxeza's drug page
4. Nevanac
Nevanac is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7834059 | Topical nepafenac formulations |
31 Jan, 2027
(2 years from now)
| Active |
| US8071648 | Topical nepafenac formulations |
02 Dec, 2025
(11 months from now)
| Active |
| US8324281 | Topical nepafenac formulations |
02 Dec, 2025
(11 months from now)
| Active |
| US5475034 | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
06 Jun, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nevanac's drug page
5. Tobradex St
Tobradex St is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7795316 | Topical ophthalmic compositions containing tobramycin and dexamethasone |
03 Aug, 2028
(3 years from now)
| Active |
| US8101582 | Topical ophthalmic compositions containing tobramycin and dexamethasone |
19 Dec, 2027
(3 years from now)
| Active |
| US8450287 | Topical ophthalmic compositions containing tobramycin and dexamethasone |
19 Dec, 2027
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tobradex St's drug page
Explore Our Curated Drug Screens
6. Triesence
Triesence is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8128960 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
17 Dec, 2029
(5 years from now)
| Active |
| US8211880 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
10 Mar, 2029
(4 years from now)
| Active |
| US6395294 | Method of visualization of the vitreous during vitrectomy |
13 Jan, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Triesence's drug page
7. Verkazia
Verkazia is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9132071 | Compositions containing quaternary ammonium compounds |
02 Jun, 2029
(4 years from now)
| Active |
| US8298568 | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
03 Nov, 2027
(2 years from now)
| Active |
| US11612658 | Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same |
27 Jan, 2026
(1 year, 1 month from now)
| Active |
| US7973081 | Emulsion compositions containing quaternary ammonium compounds |
27 Jan, 2026
(1 year, 1 month from now)
| Active |
| US8524779 | Emulsion compositions containing quaternary ammonium compounds |
27 Jan, 2026
(1 year, 1 month from now)
| Active |
| US9220694 | Emulsion compositions containing cetalkonium chloride |
27 Jan, 2026
(1 year, 1 month from now)
| Active |
| US9956289 | Emulsion compositions containing quaternary ammonium compounds |
27 Jan, 2026
(1 year, 1 month from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Verkazia's drug page
8. Vevye
Vevye is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12059449 | Ophthalmic composition for treatment of dry eye disease |
01 Apr, 2042
(17 years from now)
| Active |
| US11413323 | Ophthalmic composition for treatment of dry eye disease |
11 Oct, 2039
(14 years from now)
| Active |
| US11154513 | Semifluorinated compounds |
20 Nov, 2038
(13 years from now)
| Active |
| US10813976 | Ophthalmic compositions comprising ciclosporin |
22 Sep, 2037
(12 years from now)
| Active |
| US8614178 | Pharmaceutical composition for treatment of dry eye syndrome |
13 Dec, 2030
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vevye's drug page
9. Vigamox
Vigamox is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6716830
(Pediatric)
| Ophthalmic antibiotic compositions containing moxifloxacin |
29 Mar, 2020
(4 years ago)
| Expired |
| US7671070
(Pediatric)
| Method of treating ophthalmic infections with moxifloxacin compositions |
29 Mar, 2020
(4 years ago)
| Expired |
| US6716830 | Ophthalmic antibiotic compositions containing moxifloxacin |
29 Sep, 2019
(5 years ago)
| Expired |
| US7671070 | Method of treating ophthalmic infections with moxifloxacin compositions |
29 Sep, 2019
(5 years ago)
| Expired |
| US5607942
(Pediatric)
| 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
04 Sep, 2014
(10 years ago)
| Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
04 Mar, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vigamox's drug page
10. Zerviate
Zerviate is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9254286
(Pediatric)
| Ophthalmic formulations of cetirizine and methods of use |
09 Jan, 2033
(8 years from now)
| Active |
| US9254286 | Ophthalmic formulations of cetirizine and methods of use |
09 Jul, 2032
(7 years from now)
| Active |
| US8829005
(Pediatric)
| Ophthalmic formulations of cetirizine and methods of use |
15 Sep, 2030
(5 years from now)
| Active |
| US8829005 | Ophthalmic formulations of cetirizine and methods of use |
15 Mar, 2030
(5 years from now)
| Active |
| US9750684 | Ophthalmic formulations of cetirizine and methods of use |
15 Mar, 2030
(5 years from now)
| Active |
| US9993471 | Ophthalmic formulations of cetirizine and methods of use |
15 Mar, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zerviate's drug page